Overview
- Rosen Law Firm issued a reminder for purchasers of Novo Nordisk securities from May 7 to July 28, 2025 regarding the lead plaintiff deadline.
- Plaintiffs allege the company understated the impact of a personalization exception to compounded GLP-1 exclusions and overstated patient switching to branded alternatives.
- The complaint asserts Novo Nordisk exaggerated its ability to penetrate the GLP-1 market to drive continued growth.
- No class has been certified, and the claims have not been proven in court.
- Investors wishing to seek lead-plaintiff status must move the court by September 30, and participation may be available on a contingency-fee basis without upfront costs.